Literature DB >> 30353998

ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics.

Manuela Moriggi1, Marta Giussani2, Enrica Torretta1, Daniele Capitanio1,3, Marco Sandri2, Roberta Leone1, Sara De Palma4, Michele Vasso4, Giovanni Vozzi5,6, Elda Tagliabue2, Cecilia Gelfi1,3.   

Abstract

Tumor extracellular matrix (ECM) plays a pivotal role in outcome of breast cancer (BC) patients. Overexpression of 58 genes, encoding 43 structural ECM proteins, has been identified to determine a specific cluster of BC with accelerated metastatic potential only in the undifferentiated (grade III) phenotype. The scope of this study is to characterize protein repertoire able to predict patient outcome in BC according to ECM gene expression pattern and histological grade. The differential proteomic analysis is based on 2D-differential gel electrophoresis, MALDI-MS, bioinformatics, and immunoblotting. Results suggest a relationship among ECM remodeling, signal mechanotransduction, and metabolic rewiring in BCs characterized by a specific mRNA ECM signature and identified a set of dysregulated proteins characteristic of hormone receptors expression as fibrinogen-β chain, collagen α-1(VI) chain, and α-1B-glycoprotein. Furthermore, in triple negative tumors with ECM signature, the FGG and α5β1/αvβ3 integrins increase whereas detyrosinated α-tubulin and mimecan decrease leading to unorganized integrin presentation involving focal adhesion kinase, activation of Rho GTPases associated to epithelial mesenchymal transition. In hormone receptors negative BCs characterized by a specific ECM gene cluster, the differentially regulated proteins, identified in the present study, can be potentially relevant to predict patient's outcome.
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  2D-DIGE; ECM; TN tumors; breast cancer; mass spectrometry

Mesh:

Substances:

Year:  2018        PMID: 30353998     DOI: 10.1002/pmic.201800278

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  11 in total

1.  Identification of tumor biomarkers for pathological complete response to neoadjuvant treatment in locally advanced breast cancer.

Authors:  Prarthana Gopinath; Sridevi Veluswami; Gopal Gopisetty; Shirley Sundersingh; Swaminathan Rajaraman; Rajkumar Thangarajan
Journal:  Breast Cancer Res Treat       Date:  2022-05-21       Impact factor: 4.872

Review 2.  CAR T Cell Locomotion in Solid Tumor Microenvironment.

Authors:  Duy T Nguyen; Elizabeth Ogando-Rivas; Ruixuan Liu; Theodore Wang; Jacob Rubin; Linchun Jin; Haipeng Tao; William W Sawyer; Hector R Mendez-Gomez; Matthew Cascio; Duane A Mitchell; Jianping Huang; W Gregory Sawyer; Elias J Sayour; Paul Castillo
Journal:  Cells       Date:  2022-06-20       Impact factor: 7.666

3.  Bayesian networks established functional differences between breast cancer subtypes.

Authors:  Lucía Trilla-Fuertes; Angelo Gámez-Pozo; Jorge M Arevalillo; Rocío López-Vacas; Elena López-Camacho; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Mariana Díaz-Almirón; María Ferrer-Gómez; Hilario Navarro; Paolo Nanni; Pilar Zamora; Enrique Espinosa; Paloma Maín; Juan Ángel Fresno Vara
Journal:  PLoS One       Date:  2020-06-11       Impact factor: 3.240

Review 4.  Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors.

Authors:  Marta Giussani; Tiziana Triulzi; Gabriella Sozzi; Elda Tagliabue
Journal:  Cells       Date:  2019-01-23       Impact factor: 6.600

5.  Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients.

Authors:  Daniele Capitanio; Manuela Moriggi; Enrica Torretta; Pietro Barbacini; Sara De Palma; Agnese Viganò; Hanns Lochmüller; Francesco Muntoni; Alessandra Ferlini; Marina Mora; Cecilia Gelfi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-01-28       Impact factor: 12.910

6.  Prognostic Efficacy of Tumor-Stroma Ratio in Women With Breast Cancer: A Meta-Analysis of Cohort Studies.

Authors:  Pengli Jiang; Yulong Chen; Bin Liu
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

7.  A Novel Ex Vivo Approach Based on Proteomics and Biomarkers to Evaluate the Effects of Chrysene, MEHP, and PBDE-47 on Loggerhead Sea Turtles (Caretta caretta).

Authors:  Laura Bianchi; Silvia Casini; Lorenza Vantaggiato; Agata Di Noi; Alfonso Carleo; Enxhi Shaba; Alessandro Armini; Francesco Bellucci; Giovanni Furii; Luca Bini; Ilaria Caliani
Journal:  Int J Environ Res Public Health       Date:  2022-04-05       Impact factor: 3.390

Review 8.  Fibrosis and cancer: A strained relationship.

Authors:  Bram Piersma; Mary-Kate Hayward; Valerie M Weaver
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-03-05       Impact factor: 11.414

9.  Identification and validation of stromal-tumor microenvironment-based subtypes tightly associated with PD-1/PD-L1 immunotherapy and outcomes in patients with gastric cancer.

Authors:  Qianqian Ren; Peng Zhu; Hui Zhang; Tianhe Ye; Dehan Liu; Zhao Gong; Xiangwen Xia
Journal:  Cancer Cell Int       Date:  2020-03-24       Impact factor: 5.722

Review 10.  Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.

Authors:  Monica Neagu; Carolina Constantin; Marinela Bostan; Constantin Caruntu; Simona Rebeca Ignat; Sorina Dinescu; Marieta Costache
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-29       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.